Publications by authors named "Michael D Kaufman"

Claim this Profile
D
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, Cynthia B Leary, Molly M Hood, Michael D Kaufman

Bioorg Med Chem Lett· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors.
Timothy M Caldwell, Michael D Kaufman, Scott C Wise, Yu Mi Ahn, Molly M Hood

Bioorg Med Chem Lett· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Bryan D Smith, Michael D Kaufman, Scott C Wise, Yu Mi Ahn, Timothy M Caldwell

Mol Cancer Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, Geoffrey I Shapiro, Jordi Rodon Ahnert, Michael D Kaufman

Mol Cancer Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B Leary

Cancer Cell· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.
Allison S Harney, George S Karagiannis, Jeanine Pignatelli, Bryan D Smith, Ece Kadioglu, Michael D Kaufman

Mol Cancer Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Bryan D Smith, Michael D Kaufman, Cynthia B Leary, Benjamin A Turner, Scott C Wise

Mol Cancer Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Sheng-Bin Peng, James R Henry, Michael D Kaufman, Wei-Ping Lu, Bryan D Smith

Cancer Cell· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
James R Henry, Michael D Kaufman, Sheng-Bin Peng, Yu Mi Ahn, Timothy M Caldwell

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.
Noel A Powell, Jennifer K Hoffman, Fred L Ciske, Michael D Kaufman, Jeffrey T Kohrt

Bioorg Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.
Michael D Kaufman, R Lee, H J Norton

Mult Scler· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Wayne W Chan, Scott C Wise, Michael D Kaufman, Yu Mi Ahn, Carol L Ensinger

Cancer Cell· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
Yu Mi Ahn, Michael Clare, Carol L Ensinger, Molly M Hood, John W Lord, Michael D Kaufman

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-lumen tubes: which lumen for the gum elastic bougie?
Michael S Stix, Sana Ata, Marten Wolckenhaar, Michael D Kaufman

Anesth Analg· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004-2007.
Roman Schumann, Stephanie B Jones, Bronwyn Cooper, Scott D Kelley, Mark Vanden Bosch, Michael D Kaufman

Obesity (Silver Spring)· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to therapy: using an evidence-based protocol.
Linda A Moore, Michael D Kaufman, Robert Algozzine, Nikki Irish, Mary Martin

Rehabil Nurs· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Julie A Spicer, Gordon W Rewcastle, Michael D Kaufman, Shannon L Black, Mark S Plummer

J Med Chem· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple sclerosis: severity and progression rate in African Americans compared with whites.
Michael D Kaufman, Susan K Johnson, David Moyer, Jessica Bivens, H James Norton

Am J Phys Med Rehabil· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis